About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Lisata regains full development rights to certepetide in the Greater China RegionBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu”). The or ...

Company Developments - PAVmed Inc. (NASDAQ:PAVM) experienced a stock price surge to $16.12, marking a 160.42% increase, driven by a contract secured by its subsidiary, Lucid Diagnostics, with the U.S. Department of Veterans Affairs for the EsoGuard® Esophageal DNA Test [1][7] - Namib Minerals Ordinary Shares (NASDAQ:NAMM) saw a 145.95% increase in stock price to $2.41, with a trading volume of 103,136,334, indicating heightened investor interest possibly due to strategic developments or metal price fluctuations [2][7] - Global Interactive Technologies, Inc. (NASDAQ:GITS) reported a 93.32% rise in stock price to $1.66, reflecting growing investor interest in tech and entertainment platforms, particularly those related to K-POP and modern Korean culture [3][7] - Lisata Therapeutics, Inc. (NASDAQ:LSTA) experienced an 87.27% increase in stock price to $4.04, suggesting positive market reception for its focus on cellular therapies, despite ongoing investigations into the company [4][7] - Namib Minerals Warrants (NASDAQ:NAMMW) saw a 66.78% increase in price to $0.15, indicating investor optimism in leveraging warrants for potential gains in the mining sector [5][7] Market Dynamics - The significant price changes across these companies reflect diverse sector interests, including healthcare, biotechnology, technology, and basic materials, driven by factors such as innovative product pipelines and strategic company developments [6]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights payable under certain conditions is fair to Lisata shareholders. Halper Sadeh encourages Lisata shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade. ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious disea ...

Financial Data and Key Metrics Changes - For Q3 2025, operating expenses totaled $4.4 million, a decrease of $0.9 million or 17.3% compared to $5.3 million in Q3 2024 [6] - Research and development expenses were approximately $2 million, down from $2.5 million in Q3 2024, representing a decrease of $0.6 million or 22.9% [7] - General and administrative expenses were approximately $2.5 million, compared to $2.8 million in Q3 2024, a decrease of $0.3 million or 12.1% [8] - Net losses for Q3 2025 were $4.2 million, compared to $4.9 million in Q3 2024 [8] - As of September 30, 2025, cash and cash equivalents were approximately $19 million, projected to support operations into Q1 2027 [9] Business Line Data and Key Metrics Changes - The company achieved several development milestones for sirtepotide, including positive preliminary results from multiple studies [4] - A strategic alliance was formed with GATC Health to utilize their AI Drug Discovery Platform for identifying product candidates [5] Market Data and Key Metrics Changes - The ASCEND trial, a phase 2b study, is evaluating sirtepotide in combination with standard chemotherapy for metastatic pancreatic cancer, with preliminary data showing a positive trend in overall survival [11][13] - The Bolster trial, a phase 2a study, completed enrollment ahead of schedule, with top-line data expected in Q4 2025 [16] - The Sendafox trial, a phase 1b/2a study, showed promising early survival data, including a 60% two-year overall survival rate in pancreatic cancer patients [18] Company Strategy and Development Direction - The company is focused on expanding its development pipeline for sirtepotide across various cancer types and exploring non-oncology applications [24] - A new patent for sirtepotide was issued, extending protection until March 2040, covering its chemical structures and applications [25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macro environment affecting small-cap biotech companies, impacting stock performance despite positive clinical results [28] - The company is actively seeking partnerships to fund future phase 3 trials, emphasizing the need for collaboration to minimize shareholder dilution [35] Other Important Information - The company has secured multiple special designations from the U.S. FDA and EMA for sirtepotide [10] - The iLISTA trial, evaluating sirtepotide in combination with immunotherapy, has completed enrollment, with final data expected in Q1 2026 [21][22] Q&A Session Summary Question: When should we expect the next phase 2b data cut for Sendafox? - The timeline is under the control of the investigator, and a precise estimate cannot be provided [26] Question: Can you provide an update on the GBM trial enrollment status? - Enrollment is approximately two-thirds complete, targeting 30 patients [27] Question: What does the cash flow runway to Q1 2027 include? - It covers all operating expenses and costs to support ongoing clinical trials, but does not include assumptions for a phase 3 trial for Sendafox [27] Question: Why has the stock not reacted positively to recent clinical data? - The company attributes this to a combination of negative market forces affecting small-cap biotech and limited trading activity among shareholders [28] Question: Is there a plan to pursue additional licensing opportunities? - The company is actively pursuing new licensing opportunities internally, leveraging existing partnerships [30] Question: What are the next steps following the final analysis of the Sendafox data? - The company plans to seek partners to help fund the phase 3 trial, as raising capital independently would be challenging in the current environment [34]

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Clinical Trial Results - Certepetide has shown a 41.5% overall response rate (ORR) across all doses in a Phase 1b/2a study for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients[121]. - The median overall survival (mOS) for the certepetide-treated group in the ASCEND trial was 12.68 months, compared to 9.72 months for the placebo group[122]. - The median progression-free survival (mPFS) was 7.5 months for the certepetide-treated group in the ASCEND trial, compared to 4.7 months for the placebo group[122]. - Certepetide is currently being evaluated in multiple Phase 2 clinical studies globally for various solid tumor types[115]. - The ASCEND trial is a double-blind, randomized, placebo-controlled study evaluating two dosing regimens of certepetide in mPDAC patients[122]. - The drug has demonstrated favorable safety and tolerability profiles in ongoing clinical trials[119]. - Certepetide is designed to enhance the delivery of anti-cancer therapies by modifying the tumor microenvironment and improving drug penetration[120]. Financial Performance - The net loss for the three months ended September 30, 2025, was $4.2 million, an improvement from a net loss of $4.9 million in the same period in 2024[127]. - For the nine months ended September 30, 2025, revenue totaled $70 thousand, an increase from $0 for the same period in 2024[133]. - Net loss for the nine months ended September 30, 2025, was $13.6 million, an improvement from a net loss of $15.4 million in 2024[132]. Operating Expenses - Operating expenses decreased by $0.9 million or 17.3% to $4.4 million for the three months ended September 30, 2025, compared to $5.3 million for the same period in 2024[129]. - Operating expenses decreased by $2.3 million or 12.9%, totaling $15.2 million for the nine months ended September 30, 2025, compared to $17.5 million in 2024[134]. - General and administrative expenses were approximately $8.4 million for the nine months ended September 30, 2025, down $0.7 million or 7.6% from $9.1 million in 2024[135]. Research and Development Expenses - Research and development expenses were approximately $2.0 million for the three months ended September 30, 2025, a decrease of 22.9% from $2.5 million in the same period in 2024[130]. - Research and development expenses were approximately $6.8 million for the nine months ended September 30, 2025, a decrease of $1.6 million or 18.7% from $8.4 million in 2024[135]. Cash and Liquidity - Cash and cash equivalents as of September 30, 2025, were approximately $19.0 million, with working capital of approximately $17.0 million[139]. - Net cash used in operating activities was $12.7 million for the nine months ended September 30, 2025, compared to $14.8 million in 2024[140]. - Cash provided by investing activities totaled $15.1 million for the nine months ended September 30, 2025, primarily from net sales of marketable securities[143]. - The company expects to use existing cash balances and other means to meet short and long-term liquidity needs, including potential issuances of debt or equity securities[147]. - The company issued 197,980 shares of common stock under the ATM Agreement for net proceeds of $600,663 during the nine months ended September 30, 2025[148].

Company Overview - Lisata Therapeutics is a clinical stage pharmaceutical company focused on developing innovative therapies for cancer treatment, with a mission to improve patient outcomes [8][10]. - The company has a cash runway extending into Q1 2027 and operates with no debt, indicating strong financial health [15]. - Lisata's leadership team has extensive experience in global drug development, which is crucial for navigating the complexities of the pharmaceutical industry [12][18]. Product Development and Efficacy - Certepetide, a proprietary cyclic peptide, is designed to optimize solid tumor treatment by converting tumor stroma from a barrier to a conduit for anti-cancer drugs and selectively reducing immunosuppressive T cells [28][29]. - Certepetide improved median overall survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) to 12.68 months compared to 9.23 months for standard of care (SoC) [92]. - In the ASCEND Phase 2b study, Certepetide demonstrated a median progression-free survival (PFS) of 7.46 months versus 5.29 months for SoC, nearing statistical significance (HR 0.61, p=0.09) [96]. - Certepetide showed a 55% improvement in overall survival compared to the historical control of gemcitabine plus nab-paclitaxel [77]. - Certepetide achieved a 45% objective response rate (CR + PR) in Cohort B compared to 19% in the placebo group [101]. - Certepetide demonstrated internal consistency across two Phase 1b/2a trials, supporting its efficacy in mPDAC [79]. - Certepetide demonstrated improved overall survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) compared to standard of care, with median overall survival (mOS) of 10.32 months versus 9.23 months for the control group [107]. - In Cohort B, the median progression-free survival (mPFS) was 7.46 months for Certepetide compared to 5.29 months for placebo, with a hazard ratio (HR) of 0.61 and a p-value of 0.09 [107]. - The overall response rate (ORR) for Certepetide treated patients was 50.0%, significantly higher than the 21.1% for placebo, with 1 complete response observed in the Certepetide group [107]. - Certepetide was well tolerated, with adverse events (AEs) similar to those of standard of care, and the most common AEs included fatigue (73.85% in Cohort A) and nausea (53.85% in Cohort A) [105]. Clinical Trials and Studies - The ASCEND Phase 2b trial for first-line mPDAC has completed enrollment with 158 participants, testing gemcitabine/nab-paclitaxel with certepetide or placebo [189]. - The BOLSTER Phase 2a trial for cholangiocarcinoma has completed enrollment for both first-line and second-line cohorts, with a total of 69 participants [171]. - The CENDIFOX Phase 1b/2a trial for pancreatic, colon, and appendiceal cancers has completed enrollment with 50 participants [171]. - The ILSTA Phase 1b/2a trial for locally advanced, non-resectable PDAC has completed enrollment with 30 participants [171]. - The company is targeting mid-2026 for the final data from the BOLSTER trial, which is expected to be achieved 6 months early [175]. - The primary endpoints included Progression Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS) metrics [193]. - A Phase 1b/2a trial in China (CEND1-201) is evaluating the safety and preliminary efficacy of certepetide in 55 patients with mPDAC, with results expected to contribute to overall survival and disease control rates [193]. - The CENDIFOX trial aims to complete enrollment by Q4 2024, focusing on drug safety and overall response rates [197]. - The intervention arm of the Phase 2b study included 63 patients receiving two IV pushes of certepetide, while the control arm had 29 patients receiving placebo [191]. - The study design includes treatment on days 1, 8, and 15 every 28 days, allowing for consistent monitoring of patient responses [191]. - The trials are being conducted across approximately 30 sites, including locations in Australia and New Zealand [191]. - Preliminary data from the trials was presented at the 2023 ASCO Annual Meeting, indicating ongoing research and development efforts in the field [193]. Strategic Partnerships and Financials - Lisata has established partnerships with organizations such as Catalent, GATC Health Corp., and Qilu Pharmaceutical, which support the development and commercialization of Certepetide [32][34]. - The company is eligible to receive over $10 million in tiered development milestone payments from Catalent, along with revenue sharing on future sales [34]. - Certepetide has a robust intellectual property portfolio, including 25 granted patents and 26 pending patents, with market exclusivity of 7 to 10 years post-approval in the U.S. and EU [30]. - Lisata's strategic partnerships are expected to enhance the development of Certepetide and its combinations with other therapies, potentially leading to significant revenue growth [34]. - The company is exploring additional commercial partnership opportunities to expand the reach of Certepetide in various oncology applications [129]. - As of September 30, 2025, the company has $19.0 million in cash and investments, with no debt, providing a projected cash runway into 2027 [178]. - The company has 8.8 million common shares outstanding and 1.5 million options outstanding, with a weighted average exercise price of $40.52 for warrants [179]. Market Context and Future Outlook - The global cancer burden is projected to increase significantly, with an estimated 35 million new cases and 18.5 million deaths by 2050, highlighting the urgent need for effective cancer therapies [22][23]. - The company anticipates multiple product and business milestones over the next 12 months, indicating a proactive approach to market expansion [13]. - Certepetide's commercial prospects are bolstered by its applicability across various treatment lines for mPDAC, including first-line, second-line, and third-line therapies [123]. - Certepetide's development strategy includes rapid global registration and combination studies with various SoC regimens [71]. - The global Phase 3 trial design for Certepetide has been agreed upon with the FDA, targeting 657 patients and focusing on overall survival as the primary endpoint [134]. - Certepetide has received FDA Fast Track Designation and Orphan Drug Designations, enhancing its regulatory advantages and potential market access [130].